2013-12-11 14:25:40 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Amicus Therapeutics, Inc. (FOLD) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Amicus Therapeutics, Inc. (FOLD). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Amicus Therapeutics, Inc. investor.
Report Summary: Amicus Therapeutics, Inc. is a low quality company with a positive outlook. Amicus Therapeutics, Inc. has weak business growth and is run by inefficient management. The trend in Amicus Therapeutics, Inc. fair value exchange rate against its closest rated-competitor, Insmed Incorporated, has been depreciating over the past 2 weeks. When compared to its closest competitor, Amicus Therapeutics, Inc. shows similar undervaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three components
- business, management and price, performing an in-depth analysis of Amicus Therapeutics, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.